Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

類似資料

• The addition of the mTORr inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial
  著者:: Burnett, AK, 等
  出版事項: (2018)
• Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
  著者:: Khan, N, 等
  出版事項: (2016)
• Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
  著者:: Hills, R, 等
  出版事項: (2018)
• A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
  著者:: Burnett, A, 等
  出版事項: (2018)
• Mechanisms of response and resistance to AML therapies
  著者:: Stoilova, B, 等
  出版事項: (2020)